Literature DB >> 15021312

Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy.

Chris Verhofstede1, Ann Noë, Els Demecheleer, Nancy De Cabooter, Filip Van Wanzeele, Bea Van Der Gucht, Dirk Vogelaers, Jean Plum.   

Abstract

The aim of this study was to determine whether drug-resistant virus persists in peripheral blood mononuclear cells (PBMCs) after long-term suppression of virus replication. Proviral DNA was extracted from the PBMCs of 11 patients on long-term highly active antiretroviral therapy (HAART). Genotyping of the reverse transcriptase (RT) and protease gene of several proviral variants was performed using limiting dilution polymerase chain reaction and single-copy sequencing. All patients were on successful HAART for a mean period of 59 months but had a history of suboptimal therapy and genotypic drug resistance before. Comparison of the amino acid sequence of the RT and protease gene in the different proviral variants, with that of the plasma virus isolated before HAART treatment, revealed that the different drug-resistant viral variants that evolved during the process of gradually building up resistance were still detectable in the PBMCs in 10 of the 11 patients tested. The proportion of resistant variants was found to correlate with the time that the resistant variants had been able to replicate. These data clearly show that virus variants that are able to replicate for a certain period enter the latent reservoir and remain archived in the PBMCs for a very long period.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021312     DOI: 10.1097/00126334-200404150-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  16 in total

1.  Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.

Authors:  Kim Steegen; Stanley Luchters; Els Demecheleer; Kenny Dauwe; Kishor Mandaliya; Walter Jaoko; Jean Plum; Marleen Temmerman; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.

Authors:  Shanmugam Saravanan; Selvamurthi Gomathi; Allison Delong; Bagavathi Kausalya; Sathasivam Sivamalar; Selvamuthu Poongulali; Katherine Brooks; Nagalingeswaran Kumarasamy; Pachamuthu Balakrishnan; Sunil S Solomon; Susan Cu-Uvin; Rami Kantor
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

4.  A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.

Authors:  Daphne Monie; Rachel P Simmons; Richard E Nettles; Tara L Kieffer; Yan Zhou; Haili Zhang; Sharon Karmon; Roxann Ingersoll; Karen Chadwick; Hao Zhang; Joseph B Margolick; Thomas C Quinn; Stuart C Ray; Megan Wind-Rotolo; Michael Miller; Deborah Persaud; Robert F Siliciano
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 5.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

6.  Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Authors:  Maria J Buzón; Francisco M Codoñer; Simon D W Frost; Christian Pou; Maria C Puertas; Marta Massanella; Judith Dalmau; Josep M Llibre; Mario Stevenson; Julià Blanco; Bonaventura Clotet; Roger Paredes; Javier Martinez-Picado
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

7.  HIV drug resistance mutations in proviral DNA from a community treatment program.

Authors:  Anne Derache; Hyoung-Shik Shin; Maya Balamane; Elizabeth White; Dennis Israelski; Jeffrey D Klausner; Alexandra H Freeman; David Katzenstein
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

8.  Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency.

Authors:  Sophie M Bastarache; Thibault Mesplède; Daniel A Donahue; Richard D Sloan; Mark A Wainberg
Journal:  Viruses       Date:  2014-09-19       Impact factor: 5.048

9.  Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid.

Authors:  Natalia Stella-Ascariz; Rocio Montejano; María Martin-Vicente; Jesús Mingorance; Ignacio Pérez-Valero; José I Bernardino; Jose R Arribas
Journal:  Open Forum Infect Dis       Date:  2016-02-19       Impact factor: 3.835

10.  Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study.

Authors:  Jennifer A Brown; Herbert A Mbunkah; Thabo I Lejone; Isaac Ringera; Molisana Cheleboi; Thomas Klimkait; Karin J Metzner; Huldrych F Günthard; Niklaus D Labhardt; Roger D Kouyos; Nadine Tschumi
Journal:  Open Forum Infect Dis       Date:  2021-02-02       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.